Ziopharm Oncology to Participate in Upcoming Conferences
BOSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in two upcoming conferences:
| H.C. Wainwright 22nd Annual Global Investment Conference Date: Wednesday, September 16, 2020 Time: 9:00 a.m. ET (presentation) Cantor Virtual Global Healthcare Conference Date: Thursday, September 17, 2020 Time: 1:20 p.m. ET (fireside chat) |
To access the live webcast presentations, or the subsequent archived recordings, please visit the “Investors” section of the Ziopharm website at .
About Ziopharm Oncology, Inc.
Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit .
Investor Relations Contacts:
Ziopharm Oncology:
Chris Taylor
VP, Investor Relations and Corporate Communications
T: 617.502.1881
E:
LifeSci Advisors:
Mike Moyer
Managing Director
T: 617.308.4306
E:
Media Relations Contact:
LifeSci Communications:
Patrick Bursey
T: 646.876.4932
E:
